Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in Löfgren's syndrome

Cytokine

Volumn 69, Issue 2, 2014, Pages 272-276

  Karakaya, B ^a   van Moorsel, C H M ^a   van der Helm van Mil, A H M ^b   Huizinga, T W J ^b   Ruven, H J T ^a   van der Vis, J J ^a   Grutters, J C ^a,c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Erythema nodosum; L fgren's syndrome; Macrophage migration inhibitory factor (MIF); Sarcoidosis; Single nucleotide polymorphism (SNP)

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR 173; UNCLASSIFIED DRUG; ISOMERASE; MIF PROTEIN, HUMAN;

ADULT; ALLELE; ARTHRITIS; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; ERYTHEMA NODOSUM; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE RESPONSE; LOFGREN SYNDROME; MAJOR CLINICAL STUDY; MALE; MIF GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SARCOIDOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; SYNDROME;

ADULT; ARTHRITIS; CASE-CONTROL STUDIES; ERYTHEMA NODOSUM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SARCOIDOSIS; SYNDROME;

EID: 84938420957     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.020     Document Type: Article

References (48)

1. Bernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T., et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996, 183(1):277-282.
2. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179(6):1895-1902.
3. Donnelly S.C., Haslett C., Reid P.T., Grant I.S., Wallace W.A., Metz C.N., et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997, 3(3):320-323.
4. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005, 37(2):65-73.
5. Makita H., Nishimura M., Miyamoto K., Nakano T., Tanino Y., Hirokawa J., et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998, 158(2):573-579.
6. Baugh J.A., Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002, 30(Supp. 1):S27-S35.
7. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3(10):791-800.
8. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377(6544):68-71.
9. Donnelly S.C., Bucala R. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 1997, 3(11):502-507.
10. Barton A., Lamb R., Symmons D., Silman A., Thomson W., Worthington J., et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003, 4(7):487-491.
11. Donn R., Alourfi Z., De Benedetti F., Meazza C., Zeggini E., Lunt M., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46(9):2402-2409.
12. Yoshida T., Siltzbach L.E., Masih N., Cohen S. Serum-migration inhibitory activity in patients with sarcoidosis. Clin Immunol Immunopathol 1979, 13(1):39-46.
13. Meazza C., Travaglino P., Pignatti P., Magni-Manzoni S., Ravelli A., Martini A., et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46(1):232-237.
14. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005, 102(40):14410-14415.
15. Gamez-Pozo A., Sanchez-Navarro I., Calvo E., Agullo-Ortuno M.T., Lopez-Vacas R., Diaz E., et al. PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS ONE 2012, 7(3):e33752.
16. Bargagli E., Olivieri C., Nikiforakis N., Cintorino M., Magi B., Perari M.G., et al. Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis. Respir Physiol Neurobiol 2009, 167(3):261-267.
17. Bossini-Castillo L., Simeon C.P., Beretta L., Vonk M.C., Callejas-Rubio J.L., Espinosa G., et al. Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxford) 2011, 50(11):1976-1981.
18. Sanchez E., Gomez L.M., Lopez-Nevot M.A., Gonzalez-Gay M.A., Sabio J.M., Ortego-Centeno N., et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 2006, 7(5):433-436.
19. Amoli M.M., Donn R.P., Thomson W., Hajeer A.H., Garcia-Porrua C., Lueiro M., et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002, 29(8):1671-1673.
20. Statement on sarcoidosis joint statement of the American thoracic society (ATS), the European respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 1999, 160(2):736-755.
21. Löfgren S. Erythema nodosum: studies on etiology and pathogenesisin 185 adult cases. Acta Med Scand 1946, 124:1-197.
22. Siltzbach L.E., James D.G., Neville E., Turiaf J., Battesti J.P., Sharma O.P., et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974, 57(6):847-852.
23. Grutters J.C., Sato H., Pantelidis P., Lagan A.L., McGrath D.S., Lammers J.W., et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002, 165(8):1119-1124.
24. Mrazek F., Holla L.I., Hutyrova B., Znojil V., Vasku A., Kolek V., et al. Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005, 65(2):163-171.
25. Wysoczanska B., Bogunia-Kubik K., Suchnicki K., Mlynarczewska A., Lange A. Combined association between IFN-gamma 3,3 homozygosity and DRB1*03 in Lofgren's syndrome patients. Immunol Lett 2004, 91(2-3):127-131.
26. Grunewald J., Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009, 179(4):307-312.
27. Donn R., Alourfi Z., Zeggini E., Lamb R., Jury F., Lunt M., et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004, 50(5):1604-1610.
28. Bloom B.R., Bennett B. Relation of the migration inhibitory factor (MIF) to delayed-type hypersensitivity reactions. Ann N Y Acad Sci 1970, 169(1):258-265.
29. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966, 56(1):72-77.
30. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93(15):7849-7854.
31. Campbell P.B., Kataria Y.P., Tolson T.A. In vitro production of inhibitors of monocyte locomotion by the granuloma of sarcoidosis. Am Rev Respir Dis 1984, 130(3):417-423.
32. Arakelyan A., Kriegova E., Kubistova Z., Mrazek F., Kverka M., du Bois R.M., et al. Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. Clin Exp Immunol 2009, 155(3):457-465.
33. Requena L, Yus ES. Erythema nodosum. Dermatol Clin 2008;26(4):425,38, v.
34. Lee Y.H., Bae S.C., Song G.G. The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis. Inflamm Res 2012, 61(5):411-415.
35. Xie Q., Wang S.C., Bian G., Zhan F.L., Xie J.K., Li J. Association of MIF- 173G/C and MBL2 codon 54 gene polymorphisms with rheumatoid arthritis: a meta-analysis. Hum Immunol 2012, 73(9):966-971.
36. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N Engl J Med 2007, 357(21):2153-2165.
37. Spagnolo P., Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013, 50(5):290-297.
38. Smith G., Brownell I., Sanchez M., Prystowsky S. Advances in the genetics of sarcoidosis. Clin Genet 2008, 73(5):401-412.
39. Grunewald J. Genetics of sarcoidosis. Curr Opin Pulm Med 2008, 14(5):434-439.
40. Bowes J., Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 2008, 47(4):399-402.
41. Farivar S., Shiari R., Hadi E. Genetic susceptibility to juvenile idiopathic arthritis in Iranian children. Arch Med Res 2011, 42(4):301-304.
42. Hollenbach J.A., Thompson S.D., Bugawan T.L., Ryan M., Sudman M., Marion M., et al. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum 2010, 62(6):1781-1791.
43. Sato H., Woodhead F.A., Ahmad T., Grutters J.C., Spagnolo P., van den Bosch J.M., et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet 2010, 19(20):4100-4111.
44. Delves P.J., Roitt I.M. The immune system. N Engl J Med 2000, 343(1):37-49.
45. Delves P.J., Roitt I.M. The immune system. N Engl J Med 2000, 343(2):108-117.
46. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344(12):907-916.
47. Amoli M.M., Martin J., Miranda-Filloy J.A., Garcia-Porrua C., Ollier W.E., Gonzalez-Gay M.A. Lack of association between macrophage migration inhibitory factor gene (-173 G/C) polymorphism and cutaneous vasculitis. Clin Exp Rheumatol 2006, 24(5):576-579.
48. Amoli M.M., Garcia-Porrua C., Ollier W.E., Gonzalez-Gay M.A. Lack of association between macrophage migration inhibitory factor gene polymorphism and giant cell arteritis. J Rheumatol 2005, 32(1):74-76.